The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) is a huge mover today! The stock increased 3.78% or $0.69 on November 23, hitting $18.93. About 546,591 shares traded hands. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has declined 25.79% since April 22, 2016 and is downtrending. It has underperformed by 31.20% the S&P500.
The move comes after 7 months positive chart setup for the $1.04 billion company. It was reported on Nov, 24 by Barchart.com. We have $20.07 PT which if reached, will make NASDAQ:PTLA worth $62.40 million more.
Analysts await Portola Pharmaceuticals Inc (NASDAQ:PTLA) to report earnings on February, 24. They expect $-0.98 earnings per share, up 20.33% or $0.25 from last year’s $-1.23 per share. After $-1.64 actual earnings per share reported by Portola Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -40.24% EPS growth.
Portola Pharmaceuticals Inc (NASDAQ:PTLA) Ratings Coverage
Out of 4 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 1 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 25% are positive. Portola Pharmaceuticals has been the topic of 11 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Friday, August 19 the stock rating was downgraded by Citigroup to “Neutral”. The firm has “Overweight” rating by Morgan Stanley given on Friday, August 19. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Neutral” rating by Goldman Sachs on Monday, March 28. Citigroup maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) rating on Friday, May 27. Citigroup has “Buy” rating and $36 price target. On Friday, December 18 the stock rating was initiated by Goldman Sachs with “Buy”. The rating was maintained by Credit Suisse with “Neutral” on Friday, August 19. On Wednesday, August 5 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Outperform” rating by Credit Suisse on Monday, March 28. The company was maintained on Wednesday, August 10 by Citigroup. The company was downgraded on Tuesday, May 31 by Credit Suisse.
According to Zacks Investment Research, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment is 1.09 in 2016 Q2. Its the same as in 2016Q1. The ratio is flat, as 26 funds sold all Portola Pharmaceuticals Inc shares owned while 43 reduced positions. only 16 funds bought stakes while 59 increased positions. They now own 51.75 million shares or 1.93% less from 52.77 million shares in 2016Q1.
Rail holds 1.25% or 221,414 shares in its portfolio. Proshare Advsr Lc has 0.02% invested in the company for 49,933 shares. Checchi Advisers Ltd Company holds 373 shares or 0% of its portfolio. Blackrock Fund accumulated 1.95 million shares or 0.01% of the stock. Pinnacle Assocs last reported 0.3% of its portfolio in the stock. Fincl Bank Of America Corp De holds 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 153,922 shares. Victory Cap Mngmt holds 0% or 924 shares in its portfolio. Tfs Ltd Liability Corporation holds 27,071 shares or 0.12% of its portfolio. American Century reported 42,743 shares or 0% of all its holdings. Redmile Grp Inc Ltd Liability, a California-based fund reported 1.47M shares. American Intl Group Inc accumulated 28,356 shares or 0% of the stock. The New York-based D E Shaw & Inc has invested 0% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Balyasny Asset Mngmt Ltd reported 388,026 shares or 0.06% of all its holdings. Blackrock Institutional Trust Com Na reported 1.35M shares or 0.01% of all its holdings. Metropolitan Life Ins Com Ny holds 0.01% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 35,298 shares.
More recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Fool.com which released: “Why Portola Pharmaceuticals Inc Is Plunging Today” on August 18, 2016. Also Fool.com published the news titled: “Why Portola Pharmaceuticals, Inc. Increased 11.6% in April” on May 11, 2016. Fool.com‘s news article titled: “Portola Pharmaceuticals: Does New Data Get It Back on Track?” with publication date: May 28, 2016 was also an interesting one.
PTLA Company Profile
Portola Pharmaceuticals, Inc., incorporated on September 2, 2003, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. The Company’s third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Firm has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.